AUTHORS
Yan Yin, MS, Zhiyan Liang2, Baisong Li, MS3, Daojie Liu, BS4, Xiao Han, BS5, Dajun Yang, MD, PhD6, Yifan Zhai, MD, PhD7
AFFILIATIONS
1 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
2 Ascentage Pharma Group Inc., Rockville, Maryland, United States
3 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
4 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
5 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
6 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
7 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
ABSTRACT
Background
Therapeutic options for DLBCL, a common and aggressive subtype of non-Hodgkin lymphoma, remain limited, particularly for patients harboring EZH2 gain-of-function mutations. Recurrent EZH2 activating mutations occur in ~20% to 25% of germinal center–derived DLBCL and follicular lymphoma cases and drive oncogenic PRC2‑mediated H3K27 trimethylation. This epigenetic change results in repression of cell differentiation and tumor suppressor gene expression, promoting lymphoma cell survival and proliferation. BCL-2 overexpression is common in DLBCL and contributes to apoptosis resistance and inferior clinical outcomes. APG-5918 is a potent, selective EED inhibitor that disrupts PRC2 function. Lisaftoclax (APG-2575) is a selective BCL-2 inhibitor (BCL-2i). This study evaluated the antitumor activity of APG-5918 alone and combined with BCL-2i lisaftoclax in preclinical DLBCL models.
Methods
In vitro antiproliferative activity of APG-5918, alone and combined with lisaftoclax, was evaluated in a panel of EZH2-mutant (EZH2mut) and wild-type (EZH2WT) DLBCL cell lines, using the CellTiter-Glo® assay. Molecular mechanism of action was investigated by western blotting. In vivo antitumor efficacy was assessed in EZH2mut human DLBCL cell-derived xenograft (CDX) models.
Results
APG-5918 demonstrated potent antiproliferative activity in multiple EZH2mut DLBCL cell lines with nanomolar IC₅₀ values and approximately five-fold greater potency than the EZH2 inhibitor tazemetostat. In selected EZH2WT GCB‑type lymphoma cell lines, including Toledo and DOHH2, APG-5918 retained submicromolar IC₅₀ values, whereas EED inhibitor MAK683 and tazemetostat were more than 10-fold less potent in these models. In vivo, APG-5918 exhibited robust, dose-dependent antitumor activity across several EZH2mut DLBCL xenograft models. In the Pfeiffer CDX model, APG-5918 administered once daily at 10, 30, or 90 mg/kg for 21 days induced profound tumor suppression. APG-5918 achieved a 100% objective response rate at both 30 and 90 mg/kg, with durable complete tumor regression sustained through day 101. Similarly, in the KARPAS-422 CDX model, APG-5918 achieved near-complete tumor suppression at 30 mg/kg (T/C = 0.48% on day 32 [D32]; ORR = 60%) and rapid, durable complete tumor regression at 90 mg/kg (T/C = 0.00% on D32; ORR = 100%). Furthermore, APG-5918 synergized with lisaftoclax to enhance antitumor activity in both in vitro and in vivo models. The combination synergistically suppressed proliferation in KARPAS-422 and SU-DHL-6 cells. APG-5918 (30 mg/kg) in combination with lisaftoclax (50 mg/kg) enhanced tumor growth inhibition (T/C = 0.12% on D32) compared with APG-5918 (T/C = 0.48%) and lisaftoclax (T/C = 46.19%) monotherapy in the KARPAS-422 CDX model, with a synergistic index of 1.90. Similarly, in the SU-DHL-6 CDX model, APG-5918 (30 mg/kg) and lisaftoclax (50 mg/kg) each exhibited significant antitumor activity (T/C = 36.29% and 30.12% on D15, respectively), whereas the combination markedly enhanced tumor growth inhibition (T/C = 4.56%), with a synergistic index of 2.40. Mechanistically, APG-5918 suppressed PRC2 functions in EZH2mut KARPAS-422 cells, as evidenced by marked reductions in EZH2, EED, and the repressive histone mark H3K27me3. This epigenetic modification was accompanied by cell cycle blockade, reflected by decreased pRb. Concomitantly, APG-5918 activated intrinsic apoptotic pathways, characterized by upregulation of proapoptotic proteins BIM and PUMA, downregulation of the antiapoptotic protein MCL-1, and enhanced PARP cleavage. Importantly, combined EED inhibition by APG-5918 and BCL-2 blockade by lisaftoclax further amplified PRC2 suppression, cell cycle arrest, and apoptotic signaling. These were evidenced by deeper reductions in EZH2, EED, H3K27me3, and pRb, together with robust induction of BIM, PUMA, and cleaved PARP.
Conclusion
APG-5918 exhibited potent single-agent antitumor activity and synergized with BCL‑2i lisaftoclax in multiple preclinical DLBCL models. Mechanistically, APG-5918 suppressed PRC2 signaling and activated intrinsic apoptotic pathways, while dual EED and BCL-2 inhibition further enhanced epigenetic suppression and cell cycle blockade, thereby potentiating apoptotic tumor cell death. Collectively, these findings provide a strong rationale to evaluate APG-5918, both as monotherapy and combined with BCL-2 inhibition, in patients with EZH2mut DLBCL.
DISCLOSURES
Yan Yin, MS: Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China - Current equity holder in publicly-traded company; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China - Stock (publicly traded); Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China - Current Employment